background
hivinfect
patient
predict
cytomegaloviru
cmv
diseas
remain
difficult
protect
role
mannanbind
lectin
mbl
ficolin
cmv
diseas
report
transplant
impact
hivinfect
patient
unclear
method
casecontrol
studi
nest
within
swiss
hiv
cohort
studi
investig
associ
plasma
level
mblficolin
cmv
diseas
compar
hivinfect
patient
cmv
diseas
case
cmvseroposit
patient
without
cmv
diseas
control
match
tcell
sampl
time
use
combin
antiretrovir
therapi
mbl
mficolin
lficolin
hficolin
quantifi
use
elisa
result
analys
case
match
control
cmv
diseas
neither
associ
mbl
odd
ratio
per
log
ngml
increas
ci
ficolin
per
log
ngml
increas
ci
ci
ci
mficolin
lficolin
hficolin
respect
found
evid
greater
associ
mbl
cmv
diseas
patient
low
count
howev
multivari
analysi
cmv
diseas
like
patient
increas
hiv
rna
per
log
copiesml
ci
shorter
durat
hivinfect
per
year
ci
cytomegaloviru
cmv
latent
infect
gener
popul
achiev
control
cmv
replic
prevent
tissueinvas
cmv
diseas
cmvspecif
tcell
essenti
patient
prolong
immunosuppress
substanti
reduct
cmvspecif
tcell
associ
increas
risk
cmv
reactiv
progress
replic
diseas
hivinfect
lead
signific
reduct
tcell
count
exhaust
tcell
function
declin
tcell
cellsml
serv
surrog
marker
advanc
state
immunosuppress
increas
risk
cmv
diseas
signific
reduct
cmvspecif
tcell
describ
advanc
state
immunosuppress
addit
cmv
diseas
rare
antiretrovir
treatment
stabl
immun
recoveri
nevertheless
hivinfect
patient
impact
cmvspecif
tcell
cmv
replic
remain
controversi
increas
overal
tcell
frequenc
associ
significantli
less
cmv
diseas
howev
singh
colleagu
report
reduct
cmvspecif
tcell
individu
histori
cmv
diseas
despit
normal
tcell
reconstitut
addit
cmvspecif
tcell
shown
poorli
predict
cmv
retin
hivaid
patient
suggest
potenti
role
immunolog
cofactor
clinic
state
impair
adapt
immun
transplant
hivinfect
innat
immun
respons
may
becom
decis
factor
enabl
host
gain
control
viru
replic
mannanbind
lectin
mbl
ficolin
compon
innat
immun
respons
integr
complement
pathway
activ
mbl
oligom
homotrimer
protein
subunit
synthesis
liver
bind
oligomer
form
carbohydr
bacteria
fungi
virus
mbl
found
bind
directli
virion
number
differ
viru
famili
includ
human
immunodefici
viru
sever
acut
respiratori
syndrom
coronaviru
influenza
viru
ebola
viru
dengu
viru
west
nile
viru
interact
subsequ
shown
lead
neutral
deposit
complement
viru
subsequ
prevent
interact
viru
host
cell
lead
increas
phagocytosi
lysi
viru
regard
cmv
evid
involv
lectin
pathway
controversi
cmv
glycoprotein
potenti
target
mbl
bind
could
prevent
virion
entri
host
cell
altern
mbl
could
recogn
glycoprotein
inon
surfac
infect
cell
subsequ
induc
complementmedi
cell
destruct
viral
reservoir
infect
cell
contrast
previou
studi
complement
activ
deposit
surfac
cmv
infect
human
skin
fibroblast
depend
mbl
initi
molecul
classic
pathway
complement
similar
mbl
mficolin
lficolin
hficolin
also
show
oligom
trimer
subunit
util
activ
enzym
howev
effect
mbl
ficolin
activ
complex
fulli
understood
intriguingli
mani
virus
encod
homologu
complement
regulatori
protein
interact
complement
receptor
virusinduc
alter
complement
function
may
increas
viru
persist
limit
immunemedi
tissu
destruct
thu
complement
may
play
role
innat
adapt
antivir
immun
respons
mbl
level
show
limit
acut
phase
chang
therebi
onetim
measur
might
suffici
determin
lifelong
plasma
level
interestingli
one
third
gener
popul
carri
genet
polymorph
associ
function
mbl
defici
thu
wherea
ficolin
defici
rare
mbl
defici
may
constitut
common
immun
deficit
human
function
defici
mbl
found
associ
increas
risk
cmv
diseas
recipi
solid
organ
hematopoiet
stem
cell
transplant
howev
data
role
function
mbl
defici
due
mbl
polymorph
transplant
patient
cmv
replic
conflict
highlight
need
defin
impact
function
mbl
defici
differ
popul
impair
immun
function
relev
mbl
ficolin
hivinfect
patient
respect
cmv
diseas
unknown
hypothesis
function
mbl
defici
risk
factor
cmv
diseas
hiv
patient
therefor
hivinfect
patient
cmv
diseas
lower
serum
mbl
ficolin
level
compar
match
hivinfect
individu
cmv
antibodi
without
cmv
diseas
furthermor
mbl
ficolin
might
confer
enhanc
protect
cmv
diseas
immunodefici
increas
conduct
match
casecontrol
studi
nest
within
swiss
hiv
cohort
studi
shc
main
centr
basel
bern
geneva
lausann
lugano
st
gallen
describ
detail
elsewher
determin
plasma
level
mbl
primari
exposur
variabl
mficolin
lficolin
hficolin
respect
secondari
exposur
variabl
two
group
patient
compar
hivinfect
patient
cmv
diseas
case
hivinfect
individu
cmv
antibodi
without
cmv
diseas
control
patient
concurr
opportunist
diseas
exclud
patient
gave
written
inform
consent
enrol
shc
http
wwwshcsch
studi
evalu
scientif
committe
shc
project
number
subsampl
dna
materi
detect
genet
differ
cmv
case
match
control
envisag
howev
genet
inform
consent
introduc
juli
avail
dna
primarili
driven
year
consent
consent
patient
select
dna
sampl
closest
index
date
cmv
diseas
date
elig
case
patient
incid
cmv
diseas
definit
see
case
requir
tcell
count
measur
concurr
plasma
sampl
taken
within
day
date
cmv
diseas
first
report
index
date
avail
tcell
count
plasma
sampl
collect
least
month
index
date
analys
mbl
ficolin
level
neither
essenti
inclus
studi
case
index
date
classifi
one
four
treatment
group
combin
antiretrovir
therapi
cart
use
group
continu
cart
less
month
new
cart
group
continu
cart
month
stabl
cart
group
onoff
cart
unstabl
cart
group
cart
defin
use
least
three
antiretrovir
agent
patient
suboptim
cart
mono
dual
therapi
index
date
includ
group
interrupt
therapi
month
patient
consid
elig
control
posit
igg
anticmv
confer
risk
cmv
reactiv
patient
elig
control
start
treatment
known
cmv
antivir
activ
cidofovir
entecavir
famciclovir
foscarnet
ganciclovir
interferon
alpha
peginterferon
alpha
ribavirin
telbivudin
howev
becam
elig
day
discontinu
antivir
treatment
control
random
sampl
risk
cmv
diseas
time
index
case
detect
could
includ
case
case
later
date
act
control
case
use
match
ie
randomli
sampl
one
control
case
control
addit
match
tcell
count
valu
within
cellsml
index
case
cart
treatment
classif
one
four
group
see
use
match
ensur
adjust
tcell
count
cart
classif
allow
us
consid
homogen
associ
cmv
diseas
mbl
across
tcell
count
strata
case
avail
control
tcell
count
plasma
sampl
collect
least
month
index
date
analys
mbl
ficolin
level
infecti
outcom
classifi
accord
previous
publish
criteria
http
cmv
diseas
includ
cmv
retin
endorgan
involv
exclud
liver
spleen
lymph
node
diseas
cmv
infect
liver
lymph
node
spleen
consid
rare
diseas
exclud
cdc
aid
defin
condit
http
wwwcdcgovmmwrpreviewmmwrhtml
case
definit
accord
intern
standard
criteria
guarante
high
level
diagnost
accuraci
definit
cmv
retin
diagnos
characterist
ophthalmolog
appear
cmvdetect
polymeras
chain
reaction
pcr
respons
cmv
treatment
howev
older
case
year
code
definit
cmv
retin
relat
previou
cdcdefinit
requir
pcr
presumpt
cmv
retin
diagnos
characterist
appear
ophthalmoscop
examin
discret
patch
retin
whiten
distinct
border
spread
centrifug
manner
frequent
associ
retin
vascul
haemorrhag
necrosi
typic
find
follow
resolut
activ
diseas
residu
retin
scar
atrophi
retin
pigment
epitheli
mottl
invas
cmv
diseas
site
alway
definit
histolog
proven
cmvinfect
posit
cultur
alon
site
except
cerebrospin
fluid
without
histolog
evid
invas
diseas
consid
suffici
diagnosi
cmv
diseas
paramet
sampl
thaw
analys
simultan
mbl
lficolin
hficolin
level
quantifi
use
commerci
avail
elisa
kit
mbl
bioportoh
denmark
hand
lficolin
hycult
biotechnologyh
netherland
assay
perform
follow
manufactur
instruct
level
mficolin
determin
use
inhous
timeresolv
immunofluorometr
assay
develop
wittenborn
et
al
previous
publish
brief
well
coat
monoclon
antimficolin
incub
sampl
dilut
high
ionic
strength
buffer
edta
heat
aggreg
human
igg
bovin
igg
wash
develop
biotinyl
antimficolin
antibodi
follow
europiumlabel
streptavidin
read
timeresolv
fluoromet
mbl
genotyp
perform
previous
describ
condit
logist
regress
appropri
assess
associ
cmv
diseas
plasma
mbl
studi
abbrevi
iqr
interquartil
rang
cmv
cytomegaloviru
hiv
human
immunodefici
viru
cart
combin
antiretrovir
therapi
iri
immun
reconstitut
inflammatori
syndrom
case
diagnos
cmv
liver
spleen
lymph
node
cmv
retin
count
former
n
n
includ
exclud
cmv
diseas
case
respect
statist
repres
clinic
stage
patient
prior
index
date
base
date
includ
exclud
cmv
diseas
case
respect
first
document
posit
test
first
report
posit
test
cohort
registr
visit
herp
simplex
diseas
mucocutan
herp
simplex
ulcer
herp
zoster
multidermatom
relaps
dissemin
toxoplasmosi
toxoplasmosi
retin
toxoplasmosi
brain
within
day
index
date
match
pair
assum
common
standard
deviat
regard
mbl
among
match
set
type
error
rate
case
match
control
power
could
achiev
detect
odd
ratio
cmv
diseas
per
standard
deviat
unit
decreas
mbl
use
condit
logist
regress
estim
associ
cmv
diseas
plasma
mblm
l
hficolin
univari
analys
estim
associ
cmv
diseas
four
individu
protein
unadjust
covari
match
factor
case
diagnos
cmv
liver
spleen
lymph
node
cmv
retin
count
former
n
statist
repres
clinic
stage
patient
prior
index
date
base
date
includ
case
control
respect
first
document
posit
test
first
report
posit
test
cohort
registr
visit
avail
casecontrol
pair
match
variabl
herp
simplex
diseas
mucocutan
herp
simplex
ulcer
herp
zoster
multidermatom
relaps
dissemin
toxoplasmosi
toxoplasmosi
retin
toxoplasmosi
brain
within
day
index
date
key
question
studi
whether
mbl
confer
enhanc
protect
cmv
diseas
immunodefici
increas
address
question
ad
covari
interact
tcell
count
mbl
model
estim
interact
show
associ
cmv
diseas
mbl
chang
lower
tcell
count
addit
estim
associ
cmv
diseas
mbl
depend
tcell
count
calcul
tcell
count
strata
separ
patient
tcell
count
cellsml
tcell
count
cellsml
earlier
studi
use
mbl
categori
rather
continu
scale
suggest
protect
role
mbl
cmv
diseas
transplant
recipi
addit
analysi
therefor
repres
mbl
piecewis
linear
spline
knot
ngml
use
piecewis
linear
spline
allow
estim
associ
cmv
diseas
mbl
without
assum
continu
gradient
across
entir
rang
observ
mbl
level
rather
ngml
plasma
sampl
obtain
least
month
date
cmv
diseas
first
diagnos
essenti
patient
elig
refrain
formal
analys
order
avoid
possibl
select
bia
rather
plot
profil
past
measur
index
date
measur
measur
index
date
subcohort
genet
data
summaris
use
descript
statist
analysi
report
estim
odd
ratio
confid
interv
assess
associ
cmv
diseas
mblficolin
level
use
sa
version
sa
institut
inc
cari
nc
usa
analys
graphic
use
r
version
r
foundat
statist
comput
vienna
austria
r
addon
packag
lattic
version
may
case
incid
cmv
diseas
document
swiss
hiv
cohort
studi
shc
patient
tcell
count
measur
within
day
date
cmv
diseas
diagnosi
addit
concurr
drawn
plasma
sampl
ultim
plasma
sampl
could
retriev
case
first
episod
cmv
diseas
januari
octob
match
control
patient
includ
studi
correspond
plasma
sampl
analys
mbl
tabl
patient
characterist
includ
case
control
summaris
tabl
case
predominantli
male
median
age
year
interquartil
rang
iqr
cmv
retin
import
locat
among
case
two
patient
cmv
retin
concurr
involv
endorgan
site
fifteen
patient
diagnos
cmv
retin
presumpt
diagnosi
one
also
simultan
extraretin
diseas
half
patient
histori
prior
exposur
cart
median
tcell
count
cellsml
accord
cdc
classif
system
hivinfect
patient
case
classifi
cdc
stage
c
case
averag
shorter
durat
hivinfect
lower
tcell
count
compar
control
higher
hiv
rna
level
mbl
level
appear
stabl
rang
age
store
sampl
year
case
control
give
caus
concern
qualiti
stabil
store
plasma
sampl
data
shown
use
septemb
st
calcul
approxim
age
plasma
sampl
although
plate
test
time
span
two
week
second
set
test
octob
time
first
diagnosi
cmv
diseas
median
mbl
level
case
ngml
iqr
median
mficolin
lficolin
hficolin
level
ngml
iqr
ngml
iqr
ng
ml
iqr
respect
control
median
mbl
level
ngml
iqr
median
mficolin
lficolin
hficolin
level
ngml
iqr
ngml
iqr
ngml
iqr
respect
densiti
plot
mbl
mficolin
lficolin
hficolin
level
show
compar
distribut
among
case
control
figur
univari
condit
logist
regress
associ
found
cmv
diseas
one
mbl
mficolin
lficolin
hficolin
tabl
similarli
adjust
potenti
confound
risk
factor
cmv
diseas
consid
match
variabl
associ
found
cmv
diseas
mbl
tabl
multivari
analysi
base
casecontrol
pair
without
miss
data
regard
consid
potenti
confound
risk
factor
cmv
diseas
age
gender
hiv
rna
level
durat
hivinfect
cmv
diseas
like
femal
ci
increas
hiv
rna
level
per
log
copiesml
ci
less
like
increas
durat
hivinfect
per
year
ci
present
analysi
evid
mbl
import
immunolog
risk
factor
cmv
diseas
patient
tcell
count
cellsml
interact
ci
estim
or
per
log
ngml
ci
per
log
ng
ml
ci
patient
tcell
count
cellsml
respect
tabl
linear
spline
model
repres
function
relationship
cmv
diseas
mbl
three
differ
ngml
oppos
one
singl
continu
gradient
associ
found
cmv
diseas
mbl
either
tabl
plasma
level
mbl
three
ficolin
appear
stabl
rang
past
avail
case
control
avail
case
control
diseas
date
measur
case
match
control
figur
mbl
level
appear
follow
typic
pattern
acutephas
respons
upregul
cmv
diseas
prior
index
date
phase
reduc
mbl
ficolin
level
observ
structur
mbl
genotyp
avail
match
pair
similar
distribut
among
case
control
tabl
carri
supplementari
analysi
compar
case
control
regard
mblficolin
type
cmv
diseas
median
mbl
level
log
ngml
case
cmv
retin
n
control
iqr
respect
case
endorgan
cmv
diseas
liver
spleen
lymph
node
n
control
median
mbl
level
log
ngml
iqr
iqr
respect
similar
pattern
obviou
differ
seen
h
l
mficolin
best
knowledg
first
studi
potenti
link
mbl
cmv
diseas
hivinfect
patient
nest
casecontrol
studi
compar
hivinfect
patient
histolog
proven
tissueinvas
cmv
diseas
wellmatch
control
group
risk
cmv
reactiv
posit
cmvigg
low
tcell
count
studi
show
low
mbl
serum
ficolin
level
associ
increas
risk
cmv
diseas
hivinfect
patient
result
suggest
associ
mbl
cmv
diseas
depend
tcell
count
howev
cmv
diseas
preval
increas
hiv
rna
level
surprisingli
less
preval
increas
time
sinc
hivinfect
major
strength
studi
larg
number
high
qualiti
sampl
avail
multicent
shc
patient
sampl
clinic
inform
prospect
collect
dedic
team
infecti
diseas
specialist
hiv
studi
nurs
shc
diagnost
criteria
cmv
diseas
either
cmv
retin
cmv
diseas
site
requir
detect
pcr
andor
histolog
proof
tissueinvas
diseas
therefor
high
level
diagnost
accuraci
guarante
studi
tightli
match
respect
immunolog
confound
tcell
count
differ
maximum
cellsml
cart
utilis
match
lead
wellmatch
composit
state
immunosuppress
case
control
match
criteria
allow
us
control
potenti
confound
adapt
immun
respons
could
identifi
associ
low
plasma
mbl
level
cmv
diseas
hivinfect
individu
impact
mbl
defici
risk
factor
cmv
diseas
immunosuppress
individu
remain
controversi
children
presum
primari
cmvinfect
genotyp
associ
lower
mbl
level
frequent
observ
patient
activ
replic
anoth
studi
fail
find
correl
cmv
replic
newborn
frequenc
mbl
genotyp
transplant
sever
studi
highlight
mbl
defici
potenti
risk
factor
cmv
replic
diseas
manuel
et
al
report
increas
risk
cmv
diseas
small
studi
highrisk
cmv
seroneg
recipi
cmv
seroposit
kidney
graft
function
mbl
defici
presenc
mbl
polymorph
liver
lung
transplant
recipi
associ
increas
cmv
replic
recipi
howev
transplant
cohort
either
structur
haplotyp
aa
higher
rate
cmv
diseas
compar
patient
ao
oo
addit
mbl
measur
similar
patient
without
posttranspl
cmv
replic
none
studi
discuss
effect
immunosuppress
potenti
confound
addit
studi
show
higher
proport
function
mbl
defici
transplant
compar
healthi
individu
impli
select
bias
ficolin
defici
associ
increas
risk
bacteri
infect
munthefog
et
al
describ
case
homozyg
hficolin
defici
patient
detect
ficolin
level
recurr
infect
suggest
role
ficolin
control
bacteri
infect
studi
one
patient
show
hficolin
level
ngml
function
protect
threshold
ficolin
yet
determin
although
power
studi
determin
predict
threshold
cmv
diseas
data
indic
associ
mficolin
lficolin
hficolin
level
cmv
diseas
studi
present
limit
patient
concurr
opportunist
infect
cmv
diseas
exclud
control
group
regard
occurr
opportunist
infect
case
versu
control
could
observ
appar
dysbal
patient
group
hivinfect
patient
cmv
retin
common
manifest
cmv
diseas
wherea
diseas
entiti
extrem
rare
transplant
recipi
larg
increas
vitreou
mbl
level
patient
endophthalm
retin
vascul
describ
compar
noninflam
eye
although
specul
suggest
mbl
level
gener
might
lower
eye
therefor
biolog
activ
cmv
studi
design
assess
differ
mbl
ficolin
level
case
cmv
retin
diseas
localis
anoth
limit
lack
inform
cmv
viremia
cmv
replic
dynam
context
mbl
level
inde
patient
high
cmv
viremia
show
increas
risk
cmv
retin
might
benefit
preemptiv
antivir
therapi
cmv
diseas
particularli
cmv
retin
cmv
coliti
often
associ
absent
low
level
cmv
viremiaantigenemia
howev
studi
report
poor
posit
neg
predict
valu
cmv
viremia
regard
cmv
diseas
studi
focus
cmv
diseas
clinic
import
outcom
prospect
studi
might
address
associ
viremia
mbl
detail
cmvspecif
tcell
known
prevent
progress
cmv
replic
cmv
diseas
immunosuppress
host
measur
cmvspecif
tcell
respons
howev
import
cofactor
includ
futur
prospect
studi
summari
result
suggest
low
plasma
mbl
ficolin
level
associ
increas
risk
cmv
diseas
patient
hiv
